CID394493

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

FDA’s list of off-patent drugs suggests higher approvals of first generics in 2022

We usher in 2023 with the key highlights of the US Food and Drug Administration’s December 202

Top drugs and pharmaceutical companies of 2019 by revenues

Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-

Teva sues ex-exec romantically involved with Apotex’s CEO; Pfizer bids adieu to Brazil`s Teuto

This week, Phispers brings you two tales of alleged misuse of information involving former employees

FDA reorganizes inspection staff; Thermo Fisher buys Patheon for $ 5.2 billion

This week in Phispers, read about the extortion cyberattack and how it impacted hospitals in the UK.

Dr. Reddy’s expansion plans for API production

Unrelated to the inspection of the USFDA at the Dr. Reddys Srikakulam facility, Dr. Reddys sought pe